Biotechnology

With a new CEO known for scaling software firms, STARLIMS is betting big on agentic AI and M&A to dominate the mission-critical lab informatics market.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

Zepto Life Technology's FDA Breakthrough status for a fungal test isn't just a win for patients; it's a strategic move in liquid biopsy's new frontier.

The struggling biopharma secures cash, but its creative financing deal could dilute existing shareholder value by over 30%. A deep dive into the high-stakes world of biotech funding.

As Prime Medicine prepares for a key investor conference, its next-gen 'search and replace' gene editing technology faces a crucial test. Can it deliver on its promise?

With a potential $4 billion on the line, CytomX and Regeneron are building a new class of cancer therapies designed to act like autonomous agents in the body.

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

Nirrin Technologies launches TALOS™, a system using novel laser spectroscopy to eliminate dilution and variability, promising a new standard for biomanufacturing.

A parent-founded nonprofit is funding a landmark gene therapy trial, aiming to create the first-ever treatment for a rare neurodevelopmental disorder.

Insulet's latest Omnipod 5 enhancements are more than a software update; they're a strategic move in the diabetes tech race. Here's what it means.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

At a Vancouver gala, Neighbourhood Pharmacies didn't just give out awards; it signaled a strategic shift. Meet the leaders pushing pharmacies into a new era.

MiniMed and Abbott are partnering on a dual glucose-ketone sensor, a move that could shift diabetes care from crisis management to proactive DKA prevention.

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?

Finland's capital is inviting firms to its '90 Hour Helsinki' program, offering a fast-track to top R&D clusters without the heavy upfront investment.

A recent FDA approval for a generic cancer drug adds to a growing market, revealing the strategic alliances redefining healthcare access.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

Amidst a national pollinator crisis, a Colorado development shows how intentional design can reverse decline, offering a powerful model for urban ecology.

As Capital Edge marks 16 years by reaffirming its niche focus, we explore the explosive growth of specialized consulting driven by byzantine federal rules.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?